{"id":134305,"date":"2024-02-29T09:47:50","date_gmt":"2024-02-29T14:47:50","guid":{"rendered":"https:\/\/ccs.ca\/?post_type=news&p=134305"},"modified":"2024-04-12T09:30:07","modified_gmt":"2024-04-12T13:30:07","slug":"new-focused-update-of-the-guidelines-for-the-use-of-antiplatelet-therapy","status":"publish","type":"news","link":"https:\/\/ccs.ca\/news\/new-focused-update-of-the-guidelines-for-the-use-of-antiplatelet-therapy\/","title":{"rendered":"New: Focused Update of the Guidelines for the Use of Antiplatelet Therapy"},"content":{"rendered":"\n
Under the co-chair leadership of Drs. Kevin R. Bainey and Guillaume Marquis-Gravel, the Canadian Cardiovascular Society (CCS) and Canadian Association of Interventional Cardiology (CAIC) present the 2023 Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Antiplatelet therapy (APT)\u00a0is the foundation for the treatment and prevention of atherothrombotic events in people who have atherosclerotic cardiovascular disease.<\/p>\n\n\n\n
The last update to this CCS\/CAIC Guideline was in 2018. Since then, several randomized controlled trials on the use of antiplatelet agents in primary and secondary prevention of atherosclerotic cardiovascular disease have been published. With that new data considered, the following key messages and figures offer a range of evidence-based treatment pathways of care for your patients.<\/p>\n\n\n\n
\u201cWe pride ourselves in creating the most up-to-date evidence-based guideline document for the use of antiplatelet therapy according to seven key clinical questions we felt were applicable to the clinician in clinical practice. These guidelines are simple and user-friendly for the busy clinician in everyday practice.\u201d – Co-Chair, Dr Kevin R. Bainey.<\/p>\n\n\n\n